18106-97-3

Basic information

• Product Name: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)
• Synonyms: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI);6-(2-Pyrazinyl)-1,3,5-triazine-2,4-diamine;6-(Pyrazin-2-yl)-1,3,5-triazine-2,4-diamine;ENT-51408
• CAS NO: 18106-97-3
• Molecular Formula: C7H7 N7
• Molecular Weight: 0
• Mol File: 18106-97-3.mol

Chemical Properties

• Boiling Point: 571.1°Cat760mmHg
• Flash Point: 334°C
• Appearance: /
• Density: 1.508g/cm³
• Vapor Pressure: 4.7E-13mmHg at 25°C
• Refractive Index: 1.724
• CAS DataBase Reference: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(18106-97-3)
• EPA Substance Registry System: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(18106-97-3)

Safety Data

• Hazardous Substances Data: 18106-97-3(Hazardous Substances Data)

Usage

General Description

1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI) is a chemical compound that belongs to the class of triazine derivatives. It is also known as Pyrazinamide and has the molecular formula C5H5N5. Pyrazinamide is a synthetic antibiotic used in combination with other drugs to treat tuberculosis. It works by inhibiting the growth of the bacteria that cause tuberculosis, specifically by blocking the synthesis of the bacterial cell wall. Pyrazinamide is typically used in combination with other antibiotics as a first-line treatment for tuberculosis, and it is also used to prevent the spread of the disease in some cases.

InChI:InChI=1/C7H7N7/c8-6-12-5(13-7(9)14-6)4-3-10-1-2-11-4/h1-3H,(H4,8,9,12,13,14)

Upstream product

• 19847-12-2 2-pyrazine carbonitrile 
• 127099-85-8 N-Cyanoguanidine 
• 127099-85-8 dicyandiamide 

Relevant articles and documents

A copper(II) complex of 6-(pyrazin-2-yl)-1,3,5-triazine-2,4-diamine and L-serinate: synthesis, crystal structure, DNA-binding and molecular docking studies

A water-soluble Cu(II) complex, [Cu(pzta)(L-Ser)(ClO4)]·1.5H2O (pzta?=?6-(pyrazin-2-yl)-1,3,5-triazine-2,4-diamine; L-Ser?=?L-serinate), was synthesized and characterized by analytical and spectral techniques. In addition, the molecular structure of the complex was confirmed by single-crystal X-ray diffraction, revealing that the central Cu(II) atom was located in a six-coordinate distorted octahedral geometry. Multi-spectroscopic methods, viscosity measurements and thermal denaturation experiments revealed that the complex binds to DNA with apparent binding constant of 2.93?×?103?M?1 through a groove binding mode. The positive values of ΔH and ΔS obtained from isothermal titration calorimetry experiments indicated that hydrophobic interactions play an important role in the formation of the complex–DNA adduct. Molecular docking studies were carried out to better understand the binding mode of the complex with DNA.

Water-soluble DNA minor groove binders as potential chemotherapeutic agents: Synthesis, characterization, DNA binding and cleavage, antioxidation, cytotoxicity and HSA interactions

Two new water-soluble copper(ii)-dipeptide complexes: [Cu(glygly)(PyTA)] ClO4·1.5H2O (1) and [Cu(glygly)(PzTA)]ClO 4·1.5H2O (2) (glygly = glycylglycine anion, PyTA = 2,4-diamino-6-(2′-pyridyl)-1,3,5-triazine and PzTA = 2,4-diamino-6- (2′-pyrazino)-1,3,5-triazine), utilizing two interrelated DNA base-like ligands (PyTA and PzTA), have been synthesized and characterized. The structure elucidation for 1 performed by single crystal X-ray diffraction showed a one dimensional chain conformation in which the central copper ions arrange in a five-coordinate distorted square-pyramidal geometry. Spectroscopic titration, viscosity and electrophoresis measurements revealed that the complexes bound to DNA via an outside groove binding mode, and cleaved pBR322 DNA efficiently in the presence of ascorbate, probably via an oxidative mechanism with the involvement of OH and O2-. Notably, the complexes exhibited considerable in vitro cytotoxicity against four human carcinoma cell lines (HepG2, HeLa, A549 and U87) with IC50 values ranging from 41.68 to 159.17 μM, in addition to their excellent SOD mimics (IC50 ～ 0.091 and 0.114 μM). Besides, multispectroscopic evidence suggested their HSA-binding at the cavity containing Trp-214 in subdomain IIA with moderate affinity, mainly via hydrophobic interaction. Further, the molecular docking technique utilized for ascertaining the mechanism and mode of action towards DNA and HSA theoretically verified the experimental results.

Triazine angiogenesis inhibitors

Compounds having Formula I STR1 or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting anglogenesis in a mammal.